GILD Stock UPDATES Gilead Sciences (GILD) 110.72 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 29, 2014 at 10:42 PM

Gilead Sciences (GILD) 110.72 $GILD

Final Glance: Biotechnology companies
AP - Wed Oct 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Stock Market Today: Stocks Not Spooked by Fed's October Taper
at The Street - Wed Oct 29, 3:19PM CDT
U.S. stock markets were not spooked by the Federal Reserve's decision to end its monthly bond buying, otherwise known as quantitative easing, this month
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Stock Market Today: Stocks Fall, Treasury Yields Rise as the Fed Ends Bond Buying
at The Street - Wed Oct 29, 2:09PM CDT
U.S. stocks were falling after the Federal Reserve's Open Market Committee decided to end its monthly bond buying, otherwise known as quantitative easing, this month.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Can the Stock Market Handle the Federal Reserve Ending QE?
at The Street - Wed Oct 29, 1:15PM CDT
CNBC's "Fast Money" panel looks at life after quantitative easing program and Facebook after earnings.
HSY: 94.06 (-1.47), PNRA: 165.42 (-5.58), BWP: 17.34 (-0.11), FB: 75.86 (-4.91), C: 52.65 (+0.21), M: 57.45 (+0.18), TLT: 119.46 (+0.27), SPY: 198.11 (-0.30), QQQ: 99.81 (-0.37), GILD: 110.72 (-2.73), DIA: 169.40 (-0.26), PHM: 19.20 (-0.15), AAL: 39.94 (-0.30), TWTR: 42.08 (-1.70), X: 40.08 (+1.93)

Most active Nasdaq-traded stocks
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 110.72 (-2.73), FB: 75.86 (-4.91), ARCP: 10.00 (-2.38), MSFT: 46.62 (+0.13), GRPN: 5.79 (-0.21), AAPL: 107.34 (+0.60)

Midday Glance: Biotechnology companies
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Stocks Worsen As Fed Announcement Looms; AmTrust Dives
at Investor's Business Daily - Wed Oct 29, 12:26PM CDT
Stocks further weakened ahead of the Fed's announcement at 2 p.m. ET. The Dow Jones industrial average and the S&P 500 joined the Nasdaq in negative territory. The Nasdaq dropped 0.6%, hurt in large part byFacebook (FB) and Gilead Sciences (GILD),...
ORB: 25.27 (-5.10), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), AFSI: 46.04 (-6.99), ULTA: 121.56 (+0.59)

Stock Market Today: S&P 500 Turns Higher on Lower-Than-Forecast Oil Inventories
at The Street - Wed Oct 29, 10:01AM CDT
The S&P 500 turns higher after the Energy Information Administration said U.S. oil inventories rose 2.06 million barrels last week, a lower-than-forecast increase.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Early Glance: Biotechnology companies
AP - Wed Oct 29, 9:53AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Cramer: Don't Sell U.S. Steel or Gilead Sciences on Earnings
at The Street - Wed Oct 29, 9:53AM CDT
TheStreet's Jim Cramer said U.S. Steel is a great comeback story, while investors shouldn't give up on Gilead Sciences following its earnings report.
GILD: 110.72 (-2.73), X: 40.08 (+1.93)

Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results
at The Street - Wed Oct 29, 9:37AM CDT
Shares of Gilead Sciences (GILD) declined in morning trading Wednesday after the biotech company reported third-quarter earnings that came up short of analysts' expectations.
GILD: 110.72 (-2.73)

Stocks Stage Mixed Start; Facebook Drags Down Nasdaq
at Investor's Business Daily - Wed Oct 29, 9:31AM CDT
Stocks opened mixed Wednesday, with the Dow Jones industrial average up 0.3%, the S&P 500 up 0.2% and Facebook dragging the Nasdaq down 0.3%. Volume rose 38% on the Nasdaq and was 3% higher on the NYSE, compared to trade at the same time Tuesday. The...
AMBA: 42.35 (+0.91), GPRO: 67.89 (-1.41), V: 214.66 (-2.05), ORB: 25.27 (-5.10), BIDU: 224.55 (-4.41), GILD: 110.72 (-2.73), MET: 52.31 (+0.17), KRFT: 56.91 (-0.34)

Gilead Sciences (GILD) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Oct 29, 8:30AM CDT
The following Gilead Sciences (GILD) conference call took place on October 28, 2014, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 110.72 (-2.73)

Stock Market Today: Futures Turn Mixed Ahead of Fed Meeting as Facebook Tumbles
at The Street - Wed Oct 29, 8:12AM CDT
U.S. stock futures are mixed as the Federal Reserve concludes a two-day meeting, where the central bank is widely expected to officially end its monthly bond buying program.
V: 214.66 (-2.05), GILD: 110.72 (-2.73), FB: 75.86 (-4.91), MET: 52.31 (+0.17), XOM: 94.59 (-0.51), DB: 31.20 (-1.28), FCAU: 10.85 (+1.13), SNY: 45.22 (-2.85)

Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)

Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 110.72 (-2.73), PFE: 29.49 (+0.40), EW: 120.00 (+1.72), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95)

'Fast Money' Recap: Facebook Expenses Overshadows Great Earnings
at The Street - Wed Oct 29, 4:00AM CDT
The trading panel discussed Facebook and other companies reporting earnings including U.S. Steel and Panera Bread.
HYG: 92.49 (-0.07), EA: 38.91 (+1.43), PNRA: 165.42 (-5.58), FB: 75.86 (-4.91), NNA: 2.96 (+0.11), FCX: 28.99 (-0.04), HIG: 38.87 (+0.07), YHOO: 45.43 (-0.44), GILD: 110.72 (-2.73), CMG: 639.86 (-5.99), NDLS: 21.01 (-0.67), LOCO: 36.71 (+0.29), TWTR: 42.08 (-1.70), X: 40.08 (+1.93), AAPL: 107.34 (+0.60), APC: 91.32 (+0.97), BABA: 98.31 (-1.37)

Hepatitis C: Australia Refuses to Subsidize Costly New Drug; CBCD Reviews a Report
PRWeb - Tue Oct 28, 11:09PM CDT
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 110.72 (-2.73)

Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Oct 28, 10:58PM CDT
Investors are not loving the latest earnings report from Gilead (GILD) pushing the stock lower by 4 percent after hours.
BIIB: 315.06 (-2.97), GILD: 110.72 (-2.73), ILMN: 188.88 (-1.77)

What to Make of Gilead Sciences Inc.'s Third-Quarter Earnings Miss
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 28, 5:48PM CDT
Gilead Sciences reported its third-quarter financial results after the market closed on Tuesday, and a quick glance at the stock's price would certainly lead you to think those results weren't good, as shares fell more than 3% immediately after the...
GILD: 110.72 (-2.73)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Accelerates AI Law with Newsom's Bold Move

Pushing AI Regulations into High Gear I'll tell you what—it's about time somebody shook things up in the AI world with more than empty promises. Governor Newsom's executive order is doing just that, fast-tracking the timeline for implementing California's SB 813. This move is like giving speed boots to the legislative process, revving up the rules to ensure AI doesn't...

AI Ambassadors Rethink Arbitration's Future

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

Heafner Takes Helm at HGTC Amid Strategic Shifts

A New Era for HGTC with Dr. Heafner at the Wheel Out of the frying pan and into the fire—Dr. Lori Heafner is stepping up to lead Horry-Georgetown Technical College (HGTC) with a clean slate and a hefty load of responsibility come January 2027. After enduring an intense national search by the Area Commission, she beat out tough competition to earn the role. It's not just...

IRS Views Challenge Tax-Engineered Healthcare Schemes

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Invictus Pharmacy Secures LegitScript Certification Status

A New Chapter for Invictus Pharmacy In a world tangled up in red tape, Invictus Pharmacy somehow managed to cut a clear path by earning the LegitScript Healthcare Merchant Certification. Now, it seems like they've joined the ranks of the big players, including the likes of Amazon Pharmacy. It’s not just a shiny badge on their website, folks. It’s better access to...

Buffett Steps Down, New Faces at Berkshire Hathaway

End of an Era: Warren Buffett's Retirement Warren Buffett—there's a name that's echoed through the halls of investment for decades. Today, he's pulling down the curtain as Chairman of Berkshire Hathaway (NYSE: BRK). No fanfare, just a nod to the inevitable with his classic, humor-tinged confession: 'Father Time always wins.' Can’t argue with the man who’s seen the...

Ensuring Your Radon Mitigation System Stays Effective

Radon Mitigation: A Critical Measure for Home Safety Homeowners, you're probably aware of the ticking health time bomb known as radon. Not just an annoying gas, this colorless, odorless beast lurks quietly, threatening family health if not managed right. Mitch Kelley, a specialist in radon testing with Basement Solutions in Mankato, Minnesota, lays out a no-fuss guide to...

Debbie's Dream Foundation Launches 2026 Youth Art Contest

Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...

Debt Crisis Looms: Social Security at Risk

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Sierra Ridge Advisors Join Gateway Financial Milestone

Big Moves in the Financial Advisory World Let's dive right in. Here's a real shakeup in the advisory realm: 28 financial advisors and team members from Sierra Ridge Advisor Group are packing their bags for Gateway Financial Partners. We're talking about a significant shift involving $825 million in assets under advisement. Instead of sticking with Sierra Ridge as it...